MARC Record from marc_columbia

LEADER: 06535cam a2200877Ii 4500
001 15110172
005 20220611232249.0
006 m o d
007 cr mn|||||||||
008 160324t20162016flua ob 001 0 eng d
035 $a(OCoLC)ocn945552751
035 $a(NNC)15110172
040 $aN$T$beng$erda$epn$cN$T$dN$T$dYDXCP$dIDEBK$dOCLCF$dCRCPR$dCDX$dEBLCP$dOSU$dCOO$dOCLCQ$dUAB$dESU$dSTF$dMERUC$dOCLCQ$dHMS$dOCLCO$dOCLCQ$dU3W$dOCLCQ$dWYU$dOCLCA$dLVT$dYDX$dTYFRS$dLEAUB$dOCLCQ$dUKAHL$dUWO$dUKMGB$dOCLCQ$dK6U$dOCLCO
015 $aGBB650031$2bnb
016 7 $a101689014$2DNLM
016 7 $a017798604$2Uk
019 $a945566619$a1066643096$a1076752064$a1110595291
020 $a9781498707527$q(electronic bk.)
020 $a1498707521$q(electronic bk.)
020 $a9780429183317$q(e-book ;$qPDF)
020 $a0429183313
020 $z9781498707510
020 $z1498707513
024 7 $a10.1201/b19573$2doi
035 $a(OCoLC)945552751$z(OCoLC)945566619$z(OCoLC)1066643096$z(OCoLC)1076752064$z(OCoLC)1110595291
037 $a907476$bMIL
050 4 $aR857.N34
060 4 $aQV 785
072 7 $aHEA$x012000$2bisacsh
072 7 $aHEA$x020000$2bisacsh
072 7 $aMED$x004000$2bisacsh
072 7 $aMED$x101000$2bisacsh
072 7 $aMED$x109000$2bisacsh
072 7 $aMED$x029000$2bisacsh
072 7 $aMED$x040000$2bisacsh
072 7 $aMED$x092000$2bisacsh
082 04 $a610.28$223
049 $aZCUA
100 1 $aChowdhury, Ezharul Hoque,$eauthor.
245 10 $aNanotherapeutics :$bfrom laboratory to clinic /$cEzharul H. Chowdhury.
264 1 $aBoca Raton, FL :$bCRC Press,$c[2016]
264 4 $c©2016
300 $a1 online resource (xvii, 314 pages) :$billustrations
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
520 8 $aThe emergence of nanotherapeutics is attributable to the integration of nanotechnology, recombinant DNA technology, and synthetic organic chemistry with medicine for treating critical human diseases in a more efficient and specific molecular approach than therapy with conventionally-designed and formulated drugs. Nanotherapeutics: From Laboratory to Clinic comprehensively discusses the current shortcomings for delivery of classical (small) drugs, macromolecular therapeutics, and recombinant vaccine via the common intravascular and extravascular routes. The book describes the synthetic/chemical engineering methods as well as recombinant, hybridoma, and phage display technologies to fabricate different types of nanoparticulate carriers and drugs. It also reveals the diversified approaches undertaken by harnessing nanotechnology to overcome the multistep extracellular and intracellular barriers and to facilitate the development of novel strategies for therapeutic delivery and imaging. The author elaborates on the preclinical and clinical trials of potential nanoparticle-based products in animal models and patients and the approval/commercialization of nanotherapeutics, addressing all relevant human diseases. A focus on the above issues in a concise but illustrative manner fills the gap between the laboratory findings originating from the research on identification of cellular and systemic barriers of classical and macromolecular drugs along with development of strategies for fabrication and testing of nanotherapeutics, and the clinical outcomes emanating from the testing of the selected potential nanotherapeutics on patients of particular diseases. The book also fills a gap in the existing literature between the design and development of diversified nanotherapeutics for various purposes and the investigation and evaluation of potential barriers and resultant therapeutic efficacy of those nano-medicine formulations.
504 $aIncludes bibliographical references and index.
505 0 $aChapter 1. Emergence of nanotherapeutics : challenges in classical drug transport versus macromolecular drug design -- chapter 2. The ultimate destinations for delivery and release of nanotherapeutics -- chapter 3. Diversity of bioactive nanoparticles from biological, chemical, and physical perspectives -- chapter 4. Fabrication strategies for biofunctional nanoparticles -- chapter 5. Interactions and orientation of therapeutic drugs in the vicinity of nanoparticles -- chapter 6. Variable interactions of nanoparticles with blood, lymph, and extracellular and intracellular components -- chapter 7. Pharmacokinetics and biodistribution of nanoparticles -- chapter 8. Specific roles of nanoparticles in various steps of drug transport -- chapter 9. Nanotechnology approaches to modulate transport, release, and bioavailability of classical and emerging therapeutics -- chapter 10. Nanotechnology in the development of innovative treatment strategies -- chapter 11. Nanoparticles for therapeutic delivery in animal models of different cancers -- chapter 12. Nanoparticles for therapeutic delivery in animal models of other critical human diseases -- chapter 13. Nanomedicine in clinical trials -- chapter 14. Approved and commercialized nanomedicine -- chapter 15. Current safety issues : biodegradability, reactivity, and clearance.
588 0 $aPrint version record.
650 0 $aNanomedicine.
650 0 $aNanotechnology.
650 0 $aDrug delivery systems.
650 12 $aNanoparticles$xtherapeutic use
650 22 $aDrug Delivery Systems
650 22 $aMolecular Targeted Therapy
650 22 $aNanomedicine
650 6 $aSystèmes d'administration de médicaments.
650 6 $aNanomédecine.
650 7 $aHEALTH & FITNESS$xHolism.$2bisacsh
650 7 $aHEALTH & FITNESS$xReference.$2bisacsh
650 7 $aMEDICAL$xAlternative Medicine.$2bisacsh
650 7 $aMEDICAL$xAtlases.$2bisacsh
650 7 $aMEDICAL$xEssays.$2bisacsh
650 7 $aMEDICAL$xFamily & General Practice.$2bisacsh
650 7 $aMEDICAL$xHolistic Medicine.$2bisacsh
650 7 $aMEDICAL$xOsteopathy.$2bisacsh
650 7 $aDrug delivery systems.$2fast$0(OCoLC)fst00898667
650 7 $aNanomedicine.$2fast$0(OCoLC)fst01744350
650 7 $aNanotechnology.$2fast$0(OCoLC)fst01032639
655 0 $aElectronic books.
655 4 $aElectronic books.
776 08 $iPrint version:$tNanotherapeutics.$dCRC Pr I Llc 2016$z9781498707510
830 0 $aOnline access with DDA: Askews (Medicine)
856 40 $uhttp://www.columbia.edu/cgi-bin/cul/resolve?clio15110172$zTaylor & Francis eBooks
852 8 $blweb$hEBOOKS